A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression

In brief

The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL? Researchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder. Participants will: Take TNX-102 SL or a placebo every night at bedtime for 6 weeks Visit the clinic once every 2 weeks for checkups and tests

Key facts

Study ID

NCT07621237

Run by

Tonix Pharmaceuticals, Inc.

People needed

360

Starts

2026-06-01

Expected to finish

2028-02-01

Last updated by the study team

2026-06-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary DSM-5 diagnosis of current MDD.
• The duration of the current MDE must be between 6 weeks and 18 months.
• Without psychotic or catatonic features.
• Capable of reading and understanding English and able to provide written informed consent to participate.

You may not qualify if…

• Diagnosis of DSM-5-defined lifetime bipolar disorder (I, II, or unspecified), schizophrenia, schizoaffective disorder, MDD with psychotic features, other psychotic disorder, or antisocial personality disorder; current (past month) obsessive-compulsive disorder; current (past month) posttraumatic stress disorder; current (past 3 months) anorexia nervosa,
• Diagnosis of borderline personality disorder that is known, suspected
• Participants with comorbid generalized anxiety disorder (GAD), social anxiety disorder (SAD), or panic disorder are excluded only if the GAD, SAD, or panic disorder is considered the primary psychiatric diagnosis, rather than MDD.
• Participants with treatment refractory MDD, ie, previously having failed in their lifetime ≥2 treatments (due to inadequate efficacy) with at least 2 different classes of antidepressants of adequate dose, duration, and treatment adherence.
• History of substance use disorder and/or alcohol use disorder during the preceding 12 months
• Use of antidepressants (including ketamine/esketamine, St. John's Wort, S-adenosyl methionine, and/or trazodone used as an antidepressant) within 4 weeks of Baseline (Visit 2), except for fluoxetine, which must not be within 6 weeks of Baseline (Visit 2)

Where it is running

• Clinical Neuroscience Solutions Inc. - Orlando — Orlando, Florida, United States (enrolling)
• Delricht Research - New Orleans — New Orleans, Louisiana, United States (enrolling)
• Synergy Research - San Diego — Lemon Grove, California, United States
• Nrc Research Institute — Orange, California, United States
• Artemis Institute For Clinical Research - San Diego — San Diego, California, United States
• Sunwise Clinical Research, Llc — Walnut Creek, California, United States
• Clinical Neuroscience Solutions Inc. - Jacksonville — Jacksonville, Florida, United States
• K2 Medical Research - Maitland — Maitland, Florida, United States
• Central Miami Medical Institute Llc. — Miami, Florida, United States
• Medical Research Group of Central Florida — Orange City, Florida, United States
• K2 Medical Research - Tampa — Tampa, Florida, United States
• Evergreen Clinical Trials — Norcross, Georgia, United States
• Chicago Research Center — Chicago, Illinois, United States
• Delricht Research - Rockville — Rockville, Maryland, United States
• Activmed Practices & Research, Llc - Methuen — Methuen, Massachusetts, United States
• Redbird Research — Las Vegas, Nevada, United States
• Ima Clinical Research - Nyc Midtown — New York, New York, United States
• Coastal Carolina Research Center — North Charleston, South Carolina, United States
• Clinical Neuroscience Solutions Inc. - Memphis — Mephis, Tennessee, United States
• Austin Clinical Trial Partners — Austin, Texas, United States
• Revival Research Institute, Llc - McKinney, Tx — McKinney, Texas, United States
• Delricht Research - Plano — Plano, Texas, United States
• IMA Clinical Research- Phoenix — Phoenix, Arizona, United States
• Boeson Research Pvu — Provo, Utah, United States
• Inland Psychiatric Medical Group, Inc. - Chino — Chino, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.